Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

The registered record

Accession number

NCT05398809

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) (nih)

Registered condition naming hair loss

Alopecia Areata

Also registered on this record

Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)

Official title

A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

The first row holds the registered condition that placed this trial on the pipeline; the second holds everything else the sponsor registered on the same record. Both are shown, and shown apart rather than shaded differently, because leaving the second out would make this trial look more like a hair-loss study than its registration says it is — and because a distinction carried only by colour is not a distinction for every reader.

Interventions

• DrugRuxolitinib

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Phase 2

Allocation

na

Masking

none

Primary purpose

treatment

Enrolment

70 participants (estimated)

Sites

1 location in United States

What it measures

1. Response defined as a 30% improvement from baseline in the Severity of Alopecia Tool (SALT) score at 32 weeks.

   Time frame: 32 weeks

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

all

Age

12 Years to 75 Years

Healthy volunteers

accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

18 January 2023 (actual)

Primary completion

1 December 2027 (estimated)

Study completion

1 December 2027 (estimated)

First posted

1 June 2022 (actual)

Last update posted

22 June 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: this record registers a primary completion to the day, so a day is what is shown. Where a sponsor registers only a month, only a month is shown.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Alopecia Areata: Types, Treatment, and OutlookJAK Inhibitors for Alopecia Areata: Baricitinib, Ritlecitinib and Deuruxolitinib, Trial by Trial

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT05398809 on ClinicalTrials.gov · All 157 trials in the pipeline